R.a. Session II - 20 Jun 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
10%+ Owner
Signature
/s/ R.A. Session II
Issuer symbol
TSHA
Transactions as of
20 Jun 2023
Net transactions value
-$307,844
Form type
4
Filing time
22 Jun 2023, 16:00:11 UTC
Previous filing
08 Mar 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Sale $210,209 -295,653 -3.1% $0.7110 9,125,189 20 Jun 2023 Direct F1
transaction TSHA Common Stock Sale $97,635 -138,962 -1.5% $0.7026 8,986,227 21 Jun 2023 Direct F2
holding TSHA Common Stock 141,090 20 Jun 2023 See footnote F3
holding TSHA Common Stock 141,090 20 Jun 2023 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.78. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.719. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I.
F4 The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II.